324763-47-5

Usage

Uses

Used in Pharmaceutical Industry:
Benzeneoctanamide, N-(3-amino-2,2-dimethyl-3-oxopropyl)-δ-azido-γ-hydroxy-4-methoxy-3-(3-methoxypropoxy)-α,ζ-bis(1-methylethyl)-, (αS, γS, δS, ζS)is used as a potential pharmaceutical intermediate for the synthesis of complex drug molecules. Its unique structural features and chiral centers may contribute to the development of novel therapeutic agents with specific biological activities.
Used in Chemical Research:
BenzeneoctanaMide, N-(3-aMino-2,2-diMethyl-3-oxopropyl)δ-azido-γ-hydroxy-4-Methoxy-3-(3-Methoxypropoxy)α, ζ-bis(1-Methylethyl)-, (αS, γS, δS, ζS)is used as a research tool in the field of organic chemistry, where its complex structure and stereochemistry can be studied to understand the mechanisms of various chemical reactions and the formation of chiral centers. It may also be employed in the development of new synthetic methodologies and strategies for the preparation of complex organic molecules.
Used in Material Science:
Benzeneoctanamide, N-(3-amino-2,2-dimethyl-3-oxopropyl)-δ-azido-γ-hydroxy-4-methoxy-3-(3-methoxypropoxy)-α,ζ-bis(1-methylethyl)-, (αS, γS, δS, ζS)may be utilized in the development of new materials with specific properties, such as advanced polymers or composites. Its unique structural elements could potentially impart novel characteristics to these materials, making them suitable for various applications in material science.

InChI:InChI=1S/C30H51N5O6/c1-19(2)22(14-21-10-11-26(40-8)27(15-21)41-13-9-12-39-7)16-24(34-35-32)25(36)17-23(20(3)4)28(37)33-18-30(5,6)29(31)38/h10-11,15,19-20,22-25,36H,9,12-14,16-18H2,1-8H3,(H2,31,38)(H,33,37)/t22-,23-,24-,25-/m0/s1

Upstream product

• 324763-51-1 aminopivalinamide 
• 324763-46-4 (3S,5S)-5-{(1S,3S)-1-azido-3-{[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl}-4-methylpentyl}-dihydro-3-(1-methylethyl)furan-2(3H)-one 
• 145589-03-3 (S)-4-benzyl-3-(3-methylbutanoyl)oxazolidin-2-one 
• 191152-27-9 (3S,5S)-5-Hydroxymethyl-3-isopropyl-dihydro-furan-2-one 
• 191152-26-8 (3S,5S)-5-(tert-Butyl-diphenyl-silanyloxymethyl)-3-isopropyl-dihydro-furan-2-one 
• 192060-34-7 N-[(1S,2S)-2-hydroxy-1-methyl-2-phenylethyl]-3-N-dimethylbutyramide 
• 240821-65-2 (4S)-3-[(2S)-2-(1-methylethyl)-1-oxopent-4-en-1-yl]-4-(phenylmethyl)oxazolidin-2-one 
• 325740-55-4 (S)-5-Hydroxymethyl-3-isopropyl-dihydro-furan-2-one 
• 325740-56-5 (S)-4-Isopropyl-5-oxo-tetrahydro-furan-2-carbonyl chloride 
• 325740-59-8 tetrahydro-4-isopropyl-5-oxofuran-2-carboxylic acid 
• 325740-60-1 tetrahydro-4-isopropyl-5-oxofuran-2-carbonyl chloride 
• 172900-75-3 4-methoxy-3-(3-methoxypropoxy)benzaldehyde 
• 325740-58-7 (2S,4S)-4-Isopropyl-5-oxo-tetrahydro-furan-2-carboxylic acid benzyl ester 
• 324763-36-2 (E)-3-[4-Methoxy-3-(3-methoxy-propoxy)-phenyl]-acrylic acid 

Downstream Products

• 173334-58-2 (2S,4S,5S,7S)-5-amino-N-(3-amino-2,2-dimethyl-3-oxypropyl)-4-hydroxy-7-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-8-methyl-(2-propan-2-yl)nonanamide hemifumarate 
• 854197-13-0 (S)-2-tert-butoxycarbonylamino-3-methyl-butyric acid (1S,2S,4S)-2-azido-1-[(S)-2-(2-carbamoyl-2-methyl-propylcarbamoyl)-3-methyl-butyl]-4-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-5-methyl-hexyl ester 
• 173334-57-1 (2S,4S,5S,7S)-5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-nonanoic acid (2-carbamoyl-2-methyl-propyl)-amide 

Relevant academic research and scientific papers

A Total synthesis of aliskiren starting from D-Tartrate diester

A formal total synthesis of aliskiren was accomplished. A key in our synthesis was to use the symmetric ciscisoid-Cis-Bis-Lactone 3' as a precursor, which was prepared from D-tartrate diester. Appending the end groups and functional group transformations completed the synthesis.

PROCESS FOR THE PREPARATION OF ALISKIREN

The present invention relates to an improved process for the preparation of Aliskiren and its pharmaceutically acceptable salts comprising reducing the compound of Formula-Z in presence of catalyst and ammonia. The present invention further relates to Aliskiren hemifumarate having diastereomeric impurity less than 0.2%.(F) H3C CH3 NH2 H3C 0 H3C CH3 Formula-Z

SYNTHESIS OF ALISKIREN

The present invention provides novel process for the preparation of renin inhibitor Aliskiren or its derivatives, and its pharmaceutically acceptable salts. The present invention also provides novel intermediates used in the preparation of Aliskiren.

PROCESS FOR THE PREPARATION OF (2S,4S,5S,7S)-N-(2-CARBAMYL-2- METHYLPROPYL)-5-AMINO-4-HYDROXY-2,7-DIISOPROPYL-8-[4-METHOXY-3-(3- METHOXYPROPOXY)PHENYL]-OCTANAMIDE HEMIFUMARATE AND ITS INTERMEDIATES THEREOF

The present invention relates to a process for the preparation of (2S,4S,5S,7S)-N-(2- Carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-[4-methoxy-3-(3-methoxy propoxy )phenyl]-octanamide compound of formula- 1 and its pharmaceutically acceptable salts thereof. Further, relates to the processes for the preparation of (R)-4-(2-(halomethyl)-3- methylbutyl)-l-methoxy-2-(3-methoxypropoxy) benzene and (R)-2-(4-methoxy-3-(3-methoxy propoxy) benzyl)-3-methyIbutan-l-ol useful intermediates in the synthesis of compound of formula- 1.

AMIDE INHIBITORS OF RENIN

The present invention relates to new amide inhibitors of renin, pharmaceutical compositions thereof, and methods of use thereof

A convergent synthesis of the renin inhibitor CGP60536B

Pseudoephedrine serves as a dual purpose chiral auxiliary and protecting group in the synthesis of the novel orally active renin inhibitor CGP60536B. (C) 2000 Elsevier Science Ltd.

A convergent synthesis approach towards CGP60536B, a non-peptide orally potent renin inhibitor, via an enantiomerically pure ketolactone intermediate

We report a convergent synthesis of the potent orally active non-peptide renin inhibitor CGP60536B. The key reaction employs the coupling of the enantiopure Grignard species derived from chloride 13 with the diastereomerically pure γlactone 9b. The stereoselective reduction of the resulting ketone 14b has been thoroughly investigated. (C) 2000 Elsevier Science Ltd.